The recently launched EU BigData@Heart project consists of patient networks, learned societies, SMEs, pharmaceutical companies and academia. It has three main objectives:
- To deliver clinically relevant disease phenotypes underpinning research and innovation;
- Gain more scalable insights from real world evidence, clinical- and pharmaco-epidemiology;
- Gain advanced analytics insights driving drug development and personalised medicine.
The project will last for five year and was funded by the Innovative Medicines Initiative (IMI): a joint funding programme of the European Commission and the pharmaceutical industry.